首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1905670

日本核子造影市場報告（按產品（設備、放射性同位素）、應用（SPECT應用、PET應用）和地區分類，2026-2034年）

Japan Nuclear Imaging Market Report by Product (Equipment, Radioisotope), Application (SPECT Applications, PET Applications), and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本核醫影像市場規模達6.404億美元。展望未來， IMARC Group預計到2034年，該市場規模將達到10.947億美元，2026年至2034年間的複合年成長率（CAGR）為6.14%。該市場正經歷顯著成長，主要驅動力來自技術進步、老年人口成長以及慢性病發病率上升。政府推行的早期診斷措施、混合影像技術的應用以及為提高診斷精度和效率而加大研發投入，也推動了市場成長。

本報告解答的關鍵問題：

全球日本核子造影市場迄今表現如何？未來幾年又將如何發展？
全球日本核子造影市場的促進因素、限制因素和機會是什麼？
各個促進因素、限制因素和機會對全球日本核子造影市場有何影響？
主要區域市場有哪些？
哪些國家代表了最具吸引力的日本核子造影市場？
依產品分類，市場組成是怎樣的？
日本核子造影市場中最具吸引力的產品是什麼？
依應用領域分類，市場組成是怎樣的？
在日本核子造影市場中，最具吸引力的應用是什麼？
依地區分類，市場組成是怎樣的？
日本核子造影市場中最具吸引力的地區是哪一個？
該市場的競爭結構是怎麼樣的？
日本全球核子造影市場的主要參與者/公司有哪些？

Japan nuclear imaging market size reached USD 640.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,094.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.14% during 2026-2034. The market is experiencing significant growth mainly driven by technological advancements, growing geriatric population and increase in incidence of chronic disease. Government initiatives promoting early diagnosis, adoption of hybrid imaging technologies, significant investment in research and development (R&D) to enhance diagnostic precision and efficiency is driving the market growth.

Japan Nuclear Imaging Market Trends:

Rising Prevalence of Chronic Diseases

Rising prevalence of cancer in Japan necessitates advanced diagnostic tool which makes nuclear imaging important for early detection, accurate staging and monitoring treatment responses. According to a report published by National Library of Medicine, cancer has been the leading cause of death in Japan since 1981 accounting for 1/3 of total deaths. There were 1,019,000 new cancer cases and 380,400 cancer deaths in 2022. Techniques like PET/CT provide detailed images of cancerous tissues aiding in personalized treatment plans and improving patient outcomes. Similarly, cardiovascular disease a major health concern benefits significantly from nuclear imaging modalities such as SPECT and PET scans. These techniques help in assessing myocardial perfusion, detecting ischemia, and evaluating cardiac function, thereby facilitating timely and precise interventions. The growing reliance on nuclear imaging enhances the management of these chronic diseases, contributing to better health outcomes and prolonged patient survival.

Rising Geriatric Population

Japan's aging population significantly increases the demand for nuclear imaging services as older adults often require frequent diagnostic procedures for age-related health issues. According to an article published by BBC, national data shows that 29.1% of 125 million population in Japan is aged 65 or older. In Japan, people aged over 65 are expected to account for 34.8% of population by 2040. Conditions such as cancer, cardiovascular diseases and neurological disorders are more prevalent in elderly people which necessitates advanced imaging technologies for early detection and accurate diagnosis. Furthermore, age-related degenerative conditions such as Alzheimer disease benefits from nuclear imaging for early intervention. The rising geriatric demographic drives the Japan nuclear imaging market growth, ensuring better healthcare outcomes and quality of life for older adults.

Increase in Government Investments

Government investments in healthcare infrastructure in Japan are crucial in bolstering the nuclear imaging market. These investments include funding for state-of-the-art imaging technologies and facilities, ensuring that healthcare providers have access to the latest diagnostic tools. For instance, Japan Health 2025 aims to transform global healthcare with a focus on medical innovation and technology. The country's healthcare sector is evolving, with initiatives like the Japan Innovation Campus in Silicon Valley and advancements in Precision Medicine and regenerative medicine. Japan Health aspires to connect Japan with the world and elevate its healthcare industry to global standards. Such advancements improve diagnostic accuracy and patient care, driving the adoption of nuclear imaging. Furthermore, favorable regulatory policies support the market's growth by streamlining the approval process for new imaging technologies and radiopharmaceuticals. Government initiatives promoting research and development in nuclear imaging foster innovation and facilitate the introduction of cutting-edge techniques and treatments, ultimately enhancing the overall healthcare system and patient outcomes.

Japan Nuclear Imaging Market Segmentation:

Breakup by Product:

Equipment
Radioisotope
- SPECT Radioisotopes
Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium (Ga-67)
Iodine (I-123)
Others
- PET Radioisotopes
Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Others

The Japan nuclear imaging market for equipment is a vital component of the country's advanced healthcare infrastructure. Key equipment includes Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scanners, which are essential for diagnosing various conditions, including cancer, cardiovascular diseases, and neurological disorders. The demand for such equipment is driven by Japan's aging population, increasing prevalence of chronic diseases, and advancements in imaging technologies. Moreover, the integration of artificial intelligence and machine learning in imaging equipment enhances diagnostic accuracy and efficiency, further propelling market growth. Continuous investments in healthcare infrastructure and rising awareness about early disease detection contribute significantly to the expansion of the nuclear imaging equipment market in Japan.

Radioisotopes are fundamental to Japan's nuclear imaging market, providing the necessary tracers for both SPECT and PET imaging techniques. SPECT radioisotopes, such as Technetium-99m (Tc-99m) and Thallium-201 (Tl-201), are extensively used for cardiac, bone, and tumor imaging due to their favorable properties and availability. PET radioisotopes, including Fluorine-18 (F-18) and Rubidium-82 (Rb-82), offer high-resolution imaging crucial for detecting cancer, neurological disorders, and cardiovascular diseases. The increasing prevalence of these conditions drives the demand for both SPECT and PET radioisotopes. Japan's robust healthcare infrastructure, coupled with its focus on advanced nuclear medicine research, supports the growing utilization of these radioisotopes, ensuring precise diagnostics and effective disease management.

Breakup by Application:

SPECT Applications
- Orthopedics
- Thyroid
- Cardiology
- Others
PET Applications
- Oncology
- Cardiology
- Neurology
- Others

In Japan, SPECT applications are pivotal for diagnosing and monitoring various health conditions. Orthopedics benefits from SPECT imaging in detecting bone abnormalities and fractures. Thyroid imaging utilizes SPECT to assess thyroid function and detect disorders like hyperthyroidism or thyroid cancer. Cardiology applications use SPECT to evaluate myocardial perfusion and diagnose coronary artery disease. Other applications include brain imaging for epilepsy and dementia. The rising prevalence of these conditions, coupled with advancements in SPECT technology, drives the demand for SPECT applications in Japan's healthcare sector, ensuring precise diagnostics and improved patient outcomes.

PET applications are integral to Japan's nuclear imaging market, offering high-resolution imaging for various medical fields. Oncology heavily relies on PET for detecting and staging cancers, monitoring treatment response, and recurrence. Cardiology applications use PET to assess myocardial perfusion and viability, aiding in the diagnosis and management of heart diseases. Neurology benefits from PET imaging in diagnosing and evaluating neurological disorders like Alzheimer's disease and epilepsy. Other applications include infection and inflammation imaging. The increasing incidence of cancer, cardiovascular, and neurological diseases in Japan fuels the demand for PET applications, enhancing early detection and effective treatment strategies.

Breakup by Region

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region

The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

The Kanto Region, including Tokyo, is a significant market for nuclear imaging in Japan. As the most populous and economically developed region, it boasts advanced healthcare facilities and a high concentration of medical research institutions. The demand for nuclear imaging equipment and radioisotopes is driven by the region's large aging population and high incidence of chronic diseases. Continuous investments in healthcare infrastructure and the presence of leading medical universities further enhance the growth of the nuclear imaging market in the Kanto Region.

The Kansai/Kinki Region, encompassing cities like Osaka and Kyoto, is a crucial market for nuclear imaging in Japan. Known for its strong industrial base and prominent healthcare institutions, the region has a high demand for nuclear imaging services. The aging population and increasing prevalence of diseases such as cancer and cardiovascular disorders fuel the need for advanced diagnostic imaging. The region's focus on healthcare innovation and the presence of renowned medical research centers contribute to the expansion of the nuclear imaging market in Kansai.

The Central/Chubu Region, including Nagoya, plays a vital role in Japan's nuclear imaging market. This region's robust manufacturing industry supports the development and distribution of advanced medical equipment. The growing elderly population and the rising incidence of chronic illnesses drive the demand for nuclear imaging. Key healthcare institutions and research facilities in the region emphasize early disease detection and effective treatment, further boosting the market. Continuous advancements in nuclear imaging technology and healthcare infrastructure development are significant factors contributing to the market's growth in the Central/Chubu Region.

The Kyushu-Okinawa Region is an emerging market for nuclear imaging in Japan. Known for its diverse population and growing healthcare needs, the region sees increasing demand for advanced diagnostic imaging services. The prevalence of chronic diseases and the aging population necessitate enhanced healthcare facilities, including nuclear imaging. Investments in healthcare infrastructure and the establishment of new medical research institutions are driving market growth. The region's focus on improving healthcare accessibility and quality contributes to the expanding nuclear imaging market in Kyushu-Okinawa.

The Tohoku Region, in northeastern Japan, is progressively developing its nuclear imaging market. The region, recovering from the 2011 earthquake and tsunami, has seen significant investments in healthcare infrastructure. The aging population and increasing chronic disease rates drive the need for advanced diagnostic tools like nuclear imaging. Local healthcare institutions emphasize early detection and precise diagnostics, which fuel the demand for SPECT and PET imaging. Continuous efforts to enhance medical services and infrastructure are pivotal in the market growth in the Tohoku Region.

The Chugoku Region, located in western Honshu, is gradually expanding its nuclear imaging market. The region's healthcare needs are driven by its aging population and the increasing prevalence of chronic diseases. The demand for advanced diagnostic imaging technologies, including SPECT and PET, is rising. Investments in healthcare infrastructure and the presence of key medical universities and research centers support market growth. Efforts to improve healthcare services and accessibility contribute to the development of the nuclear imaging market in the Chugoku Region.

The Hokkaido Region, Japan's northernmost island, is witnessing growth in its nuclear imaging market. The region's healthcare system addresses the needs of an aging population and rising chronic disease cases. The demand for nuclear imaging services, including SPECT and PET, is increasing for precise diagnostics and effective treatment planning. Investments in healthcare infrastructure, coupled with initiatives to enhance medical research and technology, are driving the market. The region's focus on improving healthcare quality and accessibility supports the expansion of the nuclear imaging market in Hokkaido.

The Shikoku Region, Japan's smallest major island, is developing its nuclear imaging market. The region faces healthcare challenges due to its aging population and increasing chronic disease prevalence. The demand for advanced diagnostic imaging, such as SPECT and PET, is growing to meet these needs. Investments in healthcare facilities and efforts to improve medical services are contributing to market growth. The establishment of new medical research institutions and the focus on early disease detection are key factors driving the expansion of the nuclear imaging market in the Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
The Japan Nuclear Imaging Market is highly competitive, characterized by the presence of various key players. These companies are leading the market through technological innovations, extensive research and development, and strategic collaborations. For instance, in April 2024, FUJIFILM Toyama Chemical and Synplogen entered a strategic business alliance on CDMO services for mRNA therapeutics. This alliance expands CDMO services to cover mRNA sequence design and plasmid DNA synthesis. Synplogen will provide mRNA sequence design and plasmid DNA synthesis services. By integrating expertise in mRNA sequence design and plasmid DNA synthesis, the companies aim to maximize customer value in the mRNA therapeutics industry and support its growth. Additionally, smaller domestic companies and startups are also contributing to market dynamism by introducing niche products and services. The market's competitiveness is further intensified by the increasing adoption of nuclear imaging for early diagnosis and treatment of chronic diseases.

Key Questions Answered in This Report:

How has the global Japan nuclear imaging market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global Japan nuclear imaging market?
What is the impact of each driver, restraint, and opportunity on the global Japan nuclear imaging market?
What are the key regional markets?
Which countries represent the most attractive Japan nuclear imaging market?
What is the breakup of the market based on the product?
Which is the most attractive product in the Japan nuclear imaging market?
What is the breakup of the market based on the application?
Which is the most attractive application in the Japan nuclear imaging market?
What is the breakup of the market based on the region?
Which is the most attractive region in the Japan nuclear imaging market?
What is the competitive structure of the market?
Who are the key players/companies in the global Japan nuclear imaging market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Nuclear Imaging Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Nuclear Imaging Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Nuclear Imaging Market - Breakup by Product

6.1 Equipment
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Radioisotope
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Segmentation
  - 6.2.3.1 SPECT Radioisotopes
    - 6.2.3.1.1 Technetium-99m (TC-99m)
    - 6.2.3.1.2 Thallium-201 (TI-201)
    - 6.2.3.1.3 Gallium (Ga-67)
    - 6.2.3.1.4 Iodine (I-123)
    - 6.2.3.1.5 Others
  - 6.2.3.2 PET Radioisotopes
    - 6.2.3.2.1 Fluorine-18 (F-18)
    - 6.2.3.2.2 Rubidium-82 (RB-82)
    - 6.2.3.2.3 Others
- 6.2.4 Market Forecast (2026-2034)

7 Japan Nuclear Imaging Market - Breakup by Application

7.1 SPECT Applications
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Segmentation
  - 7.1.3.1 Orthopedics
  - 7.1.3.2 Thyroid
  - 7.1.3.3 Cardiology
  - 7.1.3.4 Others
- 7.1.4 Market Forecast (2026-2034)
7.2 PET Applications
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Segmentation
  - 7.2.3.1 Oncology
  - 7.2.3.2 Cardiology
  - 7.2.3.3 Neurology
  - 7.2.3.4 Others
- 7.2.4 Market Forecast (2026-2034)

8 Japan Nuclear Imaging Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Product
- 8.1.4 Market Breakup by Application
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Product
- 8.2.4 Market Breakup by Application
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Product
- 8.3.4 Market Breakup by Application
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Product
- 8.4.4 Market Breakup by Application
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Product
- 8.5.4 Market Breakup by Application
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Product
- 8.6.4 Market Breakup by Application
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Product
- 8.7.4 Market Breakup by Application
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Product
- 8.8.4 Market Breakup by Application
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Nuclear Imaging Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Nuclear Imaging Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis